KITE

Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers

Retrieved on: 
목요일, 10월 20, 2022
Research, Hospitals, Genetics, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, LinkedIn, U.S. Securities and Exchange Commission, Time, Cardiovascular Cell Therapy Research Network, Therapy, Medicine, Risk, Cell, Patient, Synthetic biology, Lymphatic system, Research, Twitter, CAR, Gilead Sciences, Cancer, Private Securities Litigation Reform Act, HIV, MD, Social media, Safety, Pharmaceutical industry, Vaccine, Refuge

Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (Refuge), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuges proprietary gene expression platform to develop potential treatments for blood cancers.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (Refuge), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuges proprietary gene expression platform to develop potential treatments for blood cancers.
  • Refuges proprietary platform is a synthetic biology system that utilizes an expression modulation strategy to repress or activate transcription of target genes.
  • Kite will have an exclusive license to Refuges intellectual property portfolio for use in blood cancers, as well as a library of synthetic gene expression programs for these indications.
  • Kite will also make an upfront payment to Refuge and Refuge will be eligible to receive potential performance-based regulatory milestone payments.

Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product

Retrieved on: 
월요일, 10월 3, 2022
Oncology, Health, FDA, Hospitals, Genetics, Pharmaceutical, Biotechnology, YouTube, Cancer, Hospital, U.S. Securities and Exchange Commission, Gilead Sciences, Physician, LinkedIn, Clinical trial, Chimeric antigen receptor T cell, Private Securities Litigation Reform Act, Food, Lymphatic system, Blood, FDA, Medicine, HIV, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, RVV, Risk, Social media, CAR, Securities and Exchange Commission (Philippines), Vaccine, Pharmaceutical industry, Facebook, Twitter

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production.
  • Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, augmenting its strong external supply partners.
  • This forms the largest dedicated in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial production and commercial product manufacturing.
  • The capabilities and operations are fully scalable and will allow Kite to accommodate additional vector manufacturing as cell therapy science advances.

Impact Investment Firm Good & Well funds Toronto Startup Kite Mobility accelerating unprecedented access to electric mobility options within private residences, communities and resorts.

Retrieved on: 
목요일, 9월 22, 2022
Well, GHG, Carbon, City, Entrepreneurship, MacWilliams, Partnership, Toronto Native Sons, Hand, Ontario Centre of Forensic Sciences, Ownership, CEO, One Good Well, Transport, Social change, Insurance, Good, Innovation, Renewable energy, Toy

TORONTO, Sept. 22, 2022 /PRNewswire/ - Kite Mobility, a first-to-market mobile application that connects residents and guests of private buildings with multiple all-electric transportation options announced the closing of a funding round with impact investment firm Good & Well.

Key Points: 
  • TORONTO, Sept. 22, 2022 /PRNewswire/ - Kite Mobility, a first-to-market mobile application that connects residents and guests of private buildings with multiple all-electric transportation options announced the closing of a funding round with impact investment firm Good & Well.
  • Use of funds will be primarily to attract and recruit top talent, continue to expand live projects, and report on carbon reduction impact.
  • Kite offers the latest in sustainable vehicles paired with an easy-to-use mobile app, providing near instant access to mobility.
  • Good & Well is a boutique impact investment firm based in Toronto, Canada that invests in and supports inspiring entrepreneurs driving social change.

Kite’s CAR T-cell Therapy Yescarta® First in Europe to Receive Positive CHMP Opinion for Use in Second-line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Retrieved on: 
금요일, 9월 16, 2022
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Adult, Chimeric antigen receptor T cell, Committee for Medicinal Products for Human Use, Hematology, European Medicines Agency, Axicabtagene ciloleucel, European Commission, Patient, B-cell lymphoma, SOC, CEO, Quality of life, Standard of care, CHMP, EFS, Committee, Marketing, EMA, CAR, DLBCL, Pharmaceutical industry

If approved, Yescarta will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.

Key Points: 
  • If approved, Yescarta will be the first Chimeric Antigen Receptor (CAR) T-cell therapy approved for patients in Europe who do not respond to first-line treatment.
  • The European Commission will review the CHMP opinion, and a final decision on the marketing authorization is expected in the coming months.
  • Yescarta was first approved in Europe in 2018 and is currently indicated for three types of blood cancer: Diffuse Large B-Cell Lymphoma (DLBCL); Primary Mediastinal Large B-Cell Lymphoma (PMBCL); and Follicular Lymphoma (FL).
  • Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

CytoImmune Therapeutics Appoints Remus Vezan, M.D., Ph.D., as Chief Medical Officer

Retrieved on: 
수요일, 9월 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cero, University, Lymphatic system, Program, NK, Large-cell lung carcinoma, Therapy, CAR, Food and Drug Administration, Engineering, Pharmacyclics, Multiple myeloma, Medicine, Food, Acute myeloid leukemia, Mantle cell lymphoma, Acute lymphoblastic leukemia, Leadership, Immune system, FDA, University of Bern, Adult, Industry, Patient, Waldenström's macroglobulinemia, Pharmaceutical industry, Vaccine, Medical imaging

CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced the appointment of Remus Vezan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • CytoImmune Therapeutics, a clinical-stage immuno-oncology company that is developing a novel class of engineered natural killer (NK) cell-based cancer therapies, today announced the appointment of Remus Vezan, M.D., Ph.D., as Chief Medical Officer.
  • Remus brings an ideal combination of expertise to CytoImmune, having led the successful implementation and execution of clinical development strategies for several biopharmaceutical companies focused on both immuno-oncology and cell therapies, said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of CytoImmune.
  • I am pleased to join the team at this exciting time in the evolution of the company.
  • Dr. Vezan joins CytoImmune from CERo Therapeutics where he served as Chief Medical Officer.

Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer

Retrieved on: 
화요일, 9월 6, 2022
COVID-19, Engineering, CEO, Society of Spanish Researchers in the United Kingdom (SRUK/CERU), Cancer, PACT, Solution, CAR, Executive Committee, University of Tulsa, NASDAQ, ISPE, Board, Senior, Forward-looking statement, SEC, Engineering management, Organization, GLOBE, Leadership, Costar, Nasdaq, FDA, TIL, Chemical engineering, Failure, Kite Pharma, PDA, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Management, Medical imaging, EU, Genentech, Northwestern University, Instil

DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer.

Key Points: 
  • DALLAS, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Instil) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced the appointment of Tim Moore to the role of Chief Operating Officer.
  • Prior to Instil, Mr. Moore was the President and Chief Operating Officer of PACT Pharma, a cell therapy company focusing on neo-antigen directed TCR-T cell therapy.
  • Instil Bio has built an industry-leading team of cell therapy experts whom I am honored and excited to lead in my role as Chief Operating Officer, said Tim Moore, Chief Operating Officer of Instil Bio.
  • Prior to joining Instil Bio, Mr. Moore served as the President and Chief Operating Officer at PACT Pharma since April of 2020, and as the companys President and Chief Technology Officer since October of 2019.

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

Retrieved on: 
목요일, 8월 25, 2022
COO, PACT, CEO, Solution, University of Tulsa, NASDAQ, Bachelor of Science in Biomedical Engineering, Genentech, Baxter International, Gilead Sciences, CGT, FDA, Chemical engineering, Twitter, Risk, Kite Pharma, Fine chemical, Management, Science, Northwestern University

BOTHELL, Wash., Aug. 25, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced the appointment of Timothy L. Moore to its board of directors, increasing board membership to six. Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.

Key Points: 
  • Moore brings more than 30 years of broad-based leadership experience in biopharmaceutical manufacturing and operations.
  • Mike Rice, BioLife Chairman and CEO, commented, "We are both pleased and fortunate that Tim has accepted the invitation to join our board.
  • Most recently Moore was President and COO of PACT Pharma, a cell therapy company developing transformational personalized neoTCR-T cell therapies for the eradication of solid tumors.
  • BioLife Solutions is a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets.

Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting

Retrieved on: 
화요일, 5월 17, 2022
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Medicine, Private Securities Litigation Reform Act, Social media, Securities and Exchange Commission (Philippines), Adult, Patient, U.S. Securities and Exchange Commission, Brexucabtagene autoleucel, LinkedIn, Twitter, HIV, CAR, Cancer, Gilead Sciences, Pharmaceutical industry, Sacituzumab govitecan

The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Key Points: 
  • The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
  • Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, with manufacturing operations in North America and Europe.
  • All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.
  • Gilead, the Gilead logo, Kite and the Kite logo are trademarks of Gilead Sciences, Inc., or its related companies.

Kite Receives U.S. FDA Approval of New State-of-the-Art CAR T-Cell Therapy Manufacturing Facility in Maryland

Retrieved on: 
화요일, 4월 19, 2022
Biotechnology, FDA, Engineering, Health, Manufacturing, Commercial Building & Real Estate, Pharmaceutical, Construction & Property, Stem Cells, Oncology, Other Science, Hospitals, Genetics, Science, Medicine, Balise, Clinical trial, U.S. Securities and Exchange Commission, Twitter, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Gilead Sciences, Annual report, Food, Private Securities Litigation Reform Act, Hospital, Automation, Patient, Cell, LinkedIn, Lymphatic system, Social media, CAR, Chimeric antigen receptor T cell, Physician, FDA, Industry, HIV, Risk, Partnership, Time, Cancer, Pharmaceutical industry

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland.
  • The site will produce Kites FDA approved CAR T-cell therapy used to treat blood cancer.
  • Unlike most cancer treatments, CAR T-cell therapy is a one-time treatment, available through authorized treatment centers (ATCs), or hospitals, that have experience with CAR T-cell therapy.
  • To learn more about how cell therapy is manufactured, and a look inside the new Maryland facility please click here .

Shoreline Biosciences Presents Data at AACR 2022 Demonstrating its Novel Methodology to Produce Clinical Scale iPSC-derived NK (iNK) Cells

Retrieved on: 
화요일, 4월 12, 2022
Potency (pharmacology), PM, Date, Genetic engineering, IMac, Association, IPSC, Canadian Aviation Regulations, CA, Patient, Gene editing, SAN, CSO, Technology, Time, Abstract (summary), CAR, Chimeric antigen receptor T cell, CISH, American Association for Cancer Research, Safety, NK, American Association, Multimedia, BeiGene, Ink, AACR, Cancer, Mobile phone, Vaccine, Powder metallurgy

Shoreline presented two posters demonstrating its novel methodologies to produce clinical scale iPSC-derived iNK cells.

Key Points: 
  • Shoreline presented two posters demonstrating its novel methodologies to produce clinical scale iPSC-derived iNK cells.
  • Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production.
  • Shoreline's methodology supports the production of phenotypically and functionally mature iNK cells from both wildtype and genetically engineered iPSCs.
  • In particular, the generation of iPSC-derived NK cells bearing a knock-out of the gene encoding cytokine-inducible SH2-containing protein (CISH) was described at the AACR meeting.